POCT Immunofluorescent Rapid Test Kit IgM IgG , 8mins Antigen Detection Kit

POCT of Immunofluorescent Method for SARS-CoV-2 Antibody Detection

COVID-19

There is another, more common type of rapid diagnostic test-marketed for COVID-19; a test that detects the presence of antibodies in the blood of people believed to have been infected with COVID-19. Antibodies are produced over days to weeks after infection with the virus. The strength of antibody response depends on several factors, including age, nutritional status, the severity of disease, and certain medications or infections like HIV that suppress the immune system. In some people with COVID-19, disease confirmed by molecular testing (e.g. reverse transcription-polymerase chain reaction: RT-PCR), weak, late or absent antibody responses have been reported. Studies suggest that the majority of patients develop antibody response only in the second week after the onset of symptoms. This means that a diagnosis of COVID-19 infection based on antibody response will often only be possible in the recovery phase when many of the opportunities for clinical intervention or interruption of disease transmission have already passed. Antibody detection tests targeting COVID-19 may also cross-react with other pathogens, including other human coronaviruses. and give false-positive results. Lastly, there has been discussion about whether RDTs detecting antibodies could predict whether an individual was immune to reinfection with the COVID-19 virus. There is no evidence to date to support this.

Tests to detect antibody responses to COVID-19 in the population will be critical to support the development of vaccines and to add to our understanding of the extent of infection among people who are not identified through active case finding and surveillance efforts, the attack rate in the population, and the infection fatality rate. For clinical diagnosis, however, such tests have limited utility because they cannot quickly diagnose acute infection to inform actions needed to determine the course of treatment. Some clinicians have used these tests for antibody responses to make a presumptive diagnosis of recent COVID-19 disease in cases where molecular testing was negative but where there was a strong epidemiological link to COVID-19 infection and paired blood samples (acute and convalescent) showing rising antibody levels.

Storage and stability:

The test card is valid for 15 months at 2 ℃ to 30 ℃. Transport and storage should be carried out at 2 ℃ to 30 ℃.

Parameter:

Parameter: